Background: Pharmaceutical expenditure has grown by 16% per annum in China during the past decade. This has been enhanced by increased coverage as well as incentives to physicians and hospitals. Hospital pharmacies dispense 80% of medicines in China, with medicines currently accounting for 46% of total hospital expenditure. Hospitals currently rely on revenues from procurement of medicines for their sustainability.
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